ResearcherVirginia Mason Medical CenterNo recent work listed
Scott W. Helton
Matched on ORCID iD 0000-0003-4703-9650; OpenAlex author ID A5019458871. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 47
2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper
Papers 8
- FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
- Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Co-author DOI 10.3389/fonc.2020.01112↗
- Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. Co-author DOI 10.1002/jso.25498↗
- Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged? Co-author DOI 10.1002/jso.25060↗
- Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience. Co-author DOI 10.1016/j.amjsurg.2016.04.008↗
- Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancre… Co-author DOI 10.1016/j.gie.2015.01.026↗
- Posterior 'superior mesenteric artery first' approach for resection of locally advanced pancreatic cancer. Last author DOI 10.1245/s10434-013-3431-6↗
- Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Last author DOI 10.1245/s10434-014-3486-z↗
Closest collaborators
The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- John Bart Rose · 5 shared papers, 2014–2023 · strength 0.41
- Paper FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-… DOI 10.1245/s10434-023-13353-2↗
- Paper Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of… DOI 10.1002/jso.25498↗
- Paper Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of I… DOI 10.3389/fonc.2020.01112↗
- Adnan A. Alseidi · 5 shared papers, 2014–2019 · strength 0.35
- Paper Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of… DOI 10.1002/jso.25498↗
- Paper Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients fr… DOI 10.1002/jso.25060↗
- Paper Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-i… DOI 10.1016/j.amjsurg.2016.04.008↗
- Flavio G. Rocha · 5 shared papers, 2014–2019 · strength 0.35
- Paper Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of… DOI 10.1002/jso.25498↗
- Paper Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients fr… DOI 10.1002/jso.25060↗
- Paper Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-i… DOI 10.1016/j.amjsurg.2016.04.008↗
- Vincent J. Picozzi · 4 shared papers, 2014–2018 · strength 0.24
- Paper Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients fr… DOI 10.1002/jso.25060↗
- Paper Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-i… DOI 10.1016/j.amjsurg.2016.04.008↗
- Paper Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: compa… DOI 10.1016/j.gie.2015.01.026↗
- Richard A. Kozarek MD · 3 shared papers, 2015–2019 · strength 0.21
- Paper Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of… DOI 10.1002/jso.25498↗
- Paper Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-i… DOI 10.1016/j.amjsurg.2016.04.008↗
- Paper Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: compa… DOI 10.1016/j.gie.2015.01.026↗
- Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.12
- Raëf Abdallah · 1 shared paper, 2023 · strength 0.12
- Jin‐Young Jang · 1 shared paper, 2023 · strength 0.12
- Giuseppe Malleo · 1 shared paper, 2023 · strength 0.12
- Gregory C. Wilson · 1 shared paper, 2023 · strength 0.12
- Ryan K. Schmocker · 1 shared paper, 2023 · strength 0.12
- Jin Peng He · 1 shared paper, 2023 · strength 0.12
- Sarah Maloney · 1 shared paper, 2023 · strength 0.12
- Russell F. Palm · 1 shared paper, 2023 · strength 0.12
- Yoo Jin Choi · 1 shared paper, 2023 · strength 0.12
- Hongbeom Kim · 1 shared paper, 2023 · strength 0.12
- Klaus Sahora · 1 shared paper, 2023 · strength 0.12
- Thomas Malinka · 1 shared paper, 2023 · strength 0.12
- Kuno Lehmann · 1 shared paper, 2023 · strength 0.12
- Syed Ameen Ahmad · 1 shared paper, 2023 · strength 0.12
- Laura Maggino · 1 shared paper, 2023 · strength 0.12
- Dilmurodjon Eshmuminov · 1 shared paper, 2023 · strength 0.12
- Pierre‐Alain Clavien · 1 shared paper, 2023 · strength 0.12
- Jeong Youp Park · 1 shared paper, 2023 · strength 0.12
- Lea Timmermann · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.